AMT-151 in Patients With Selected Advanced Solid Tumours

Summary

This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-151, a novel antibody-drug conjugate against folate receptor alpha, in patients with selected advanced solid tumors.

Conditions

• Advanced Solid Tumor
• Advanced Cancer
• Advanced Carcinoma
• Ovarian Cancer
• Ovarian Carcinoma
• Ovarian Epithelial Cancer
• Ovarian Endometrioid Adenocarcinoma
• Endometrial Cancer
• Endometrial Adenocarcinoma
• Endometrial Serous Adenocarcinoma
• Endometrial Endometrioid Adenocarcinoma
• Endometrial Clear Cell Adenocarcinoma
• Lung Adenocarcinoma
• Triple Negative Breast Cancer
• Pancreatic Ductal Adenocarcinoma
• Malignant Pleural Mesothelioma
• Ovarian Clear Cell Carcinoma
• Ovarian Clear Cell Adenocarcinoma
• Ovarian Mucinous Adenocarcinoma

Interventions

DRUG

AMT-151

Administered intravenously

Sponsors & Collaborators

• Tigermed Consulting Co., Ltd

  collaborator INDUSTRY

• Multitude Therapeutics Inc.

  lead INDUSTRY

Principal Investigators

• Sarwan Bishnoi · Cancer Research SA

• Richardson Gary · Cabrini Malvern Hospital

• Steven Kao · Chris O'Brien Lifehouse

• Catherine Shannon · Mater Cancer Care Centre

• Jermaine Coward · ICON Cancer Centre

• Mihitha Ariyapperuma · One Clinical Research (OCR)

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-01-25

Primary Completion

2024-01-01

Completion

2024-10-30

Countries

• Australia
• China

Study Locations